Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Oct 1;109(10):3357-3362.
doi: 10.3324/haematol.2023.283992.

Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results

Shinya Rai  1 , Won Seog Kim  2 , Kiyoshi Ando  3 , Ilseung Choi  4 , Koji Izutsu  5 , Norifumi Tsukamoto  6 , Dai Maruyama  7 , Kunihiro Tsukasaki  8 , Junya Kuroda  9 , Jun Ando  10 , Michihiro Hidaka  11 , Youngil Koh  12 , Hisashi Kato  13 , Toshiki Uchida  14 , Deok Hwan Yang  15 , Kenji Ishitsuka  16 , Kenichi Ishizawa  17 , Jin Seok Kim  18 , Hong Ghi Lee  19 , Hironobu Minami  20 , Hyeon Seok Eom  21 , Mitsutoshi Kurosawa  22 , Jae Hoon Lee  23 , Jong Seok Lee  24 , Won Sik Lee  25 , Hirokazu Nagai  26 , Takero Shindo  27 , Dok Hyun Yoon  28 , Shinichiro Yoshida  29 , Mireille Gillings  30 , Hiroshi Onogi  31 , Kensei Tobinai  5
Affiliations
Clinical Trial

Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results

Shinya Rai et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Swimmer plot showing treatment exposure and responses over time by response in 46 patients. CR: complete response; PD: progressive disease, PR: partial response, SD: stable disease for vertical axis.
Figure 2.
Figure 2.
Duration of response, progression-free survival and overall survival. (A) Kaplan-Meier plot of duration of response. (B) Kaplan-Meier plot of progression-free survival. (C) Kaplan-Meier plot of overall survival. CI: confidence interval; NR: not reached.
Figure 3.
Figure 3.
Incidence of grade ≥3 adverse events by treatment cycle. Cycles in which no grade ≥3 adverse events (AE) were reported are not included.
See this image and copyright information in PMC

References

    1. Cao HY, Li L, Xue SL, Dai HP. Chidamide: targeting epigenetic regulation in the treatment of hematological malignancy. Hematol Oncol. 2023;41(3):301-309. - PubMed
    1. Ridwansyah H, Wijaya I, Bashari MH, Sundawa Kartamihardja AH, Hernowo BS. The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: an updated systematic review. Biomol Biomed. 2023;23(5):727-739. - PMC - PubMed
    1. Rai S, Kim WS, Ando K, et al. . Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2023;108(3):811-821. - PMC - PubMed
    1. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009:523-531. - PMC - PubMed
    1. Cheson BD, Fisher RI, Barrington SF, et al. . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068. - PMC - PubMed

Substances

LinkOut - more resources